# Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.

> **NCT01848652** · PHASE2 · TERMINATED · sponsor: **University Hospital, Brest** · enrollment: 5 (actual)

## Conditions studied

- Cerebral Lymphoma B Cell Refractory

## Interventions

- **DRUG:** infusion of MYOCET

## Key facts

- **NCT ID:** NCT01848652
- **Lead sponsor:** University Hospital, Brest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The laboratory's partner on this study decides to terminate the contract with the CHRU Brest, because of the difficulty of the recruitment.
- **Last updated:** 2015-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01848652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01848652, "Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01848652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*